ADAPY (Adaptimmune Therapeutics) FCF Margin %: -254.84% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics FCF Margin %?

Adaptimmune Therapeutics ADAPY -4.00% FCF Margin % is -254.84% as of Jun. 2025.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Adaptimmune Therapeutics's Free Cash Flow for the three months ended in Jun. 2025 was $-34.86 Mil. Adaptimmune Therapeutics's Revenue for the three months ended in Jun. 2025 was $13.68 Mil. Therefore, Adaptimmune Therapeutics's FCF Margin % for the quarter that ended in Jun. 2025 was -254.84%.

As of today, Adaptimmune Therapeutics's current FCF Yield % is -3,032.75%.

The historical rank and industry rank for Adaptimmune Therapeutics's FCF Margin % or its related term are showing as below:

ADAPY' s FCF Margin % Range Over the Past 10 Years
Min: -296.4   Med: 0   Max: 0
Current: -296.4

ADAPY's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -80.565 vs ADAPY: -296.40

Adaptimmune Therapeutics FCF Margin % Related Terms

Adaptimmune Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics FCF Margin % Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,427.41 31.68 -631.76 -241.80 -42.65

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.38 -134.19 -1,097.98 -930.61 -254.84

ADAPY vs BCLI, APRE, JSPR: FCF Margin % Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's FCF Margin % falls into.


Adaptimmune Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Adaptimmune Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-75.926/178.032
=-42.65 %

Adaptimmune Therapeutics's FCF Margin for the quarter that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-34.855/13.677
=-254.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -254.84% mean?
Adaptimmune Therapeutics (ADAPY) has a FCF Margin % of -254.84% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' FCF Margin % too high?
Adaptimmune Therapeutics' current FCF Margin % is -254.84%.
How does Adaptimmune Therapeutics' FCF Margin % compare to BCLI and APRE?
Adaptimmune Therapeutics' FCF Margin % of -254.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current FCF Margin % is -254.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current FCF Margin % of -254.84%. The current FCF Margin % is -254.84%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current FCF Margin % is -254.84% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].